Gilead’s Phase‑2 PURPOSE 5 trial shows twice‑yearly lenacapavir markedly improves 52‑week PrEP persistence
Gilead Sciences reported results from the Phase 2, open‑label PURPOSE 5 study that compared a twice‑yearly injectable of lenacapavir with daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre‑exposure prophylaxis. Over 52 weeks, 85.6 % of participants receiving lenacapavir remained on PrEP versus 46.3 % of those on daily F/TDF, and no HIV infections occurred in the lenacapavir arm. The trial enrolled 267 participants in the United Kingdom and France and will be presented at HIV Glasgow 2026.
Why it matters
The company notes that higher persistence could translate into greater real‑world effectiveness of its long‑acting PrEP product, potentially expanding its market share. No analyst commentary was provided in the materials.
Key facts
- 1The PURPOSE 5 trial enrolled 267 participants in the United Kingdom and France. finanznachrichten.de
- 2Participants were randomized 2:1 to receive either twice‑yearly lenacapavir or daily oral F/TDF. finanznachrichten.de
- 3At week 52, 85.6 % (154 of 180) of the lenacapavir group remained persistent on PrEP. stocktitan.net
- 4At week 52, 46.3 % (37 of 80) of the daily F/TDF group remained persistent on PrEP. stocktitan.net
- 5Zero HIV acquisitions were reported among participants receiving lenacapavir, while one infection occurred in the F/TDF arm. stocktitan.net
- 6Serious adverse events were observed in 3.9 % of lenacapavir recipients and 3.4 % of F/TDF recipients, with no events linked to the study drug. finanznachrichten.de
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.